

**RESOLUTION 11.2019-16 (A-20)**  
**CBD OIL USE AND THE MARKETING OF CBD OIL**

**ISMS Board Action Taken on 01/25/2020**

**Adopted Resolution 11.2019-16 (A-20), as amended by the Council on Medical Service.**

Council on Medical Service Recommendation to ISMS Board on 01/25/2020

The author noted that the resolution is intended to address proliferation of false or misleading advertising related to cannabidiol (CBD) products. CBD is an active ingredient in cannabis derived from the hemp plant and is believed to help treat conditions like pain, anxiety and insomnia. Many companies that produce CBD products use “MD” or “doctor” in their names in order to associate themselves with legitimate medicine. Council members noted that many CBD products, when tested, are found to be contaminated with THC, which can cause unintended effects including employees failing drug tests. The Council supported the resolution’s intent, but due to concerns about the lack of quality control, recommended amending it to focus specifically on labeling. Because of the national scope of regulating CBD, the Council also recommended it be forwarded to the AMA for consideration.

The Council on Medical Service recommends that the ISMS Board of Trustees adopt Resolution 11.2019-16 (A-20), amended as follows:

~~RESOLVED, that ISMS create a policy specifically stating that at this time there is no proven health benefit to CBD oil beyond the single indication for the treatment of two rare epilepsy syndromes and that there are significant risks to health of taking unregulated dietary supplement CBD oil with unknown quality controls; and be it further~~

RESOLVED, that ISMS ask the Attorney General of Illinois to investigate companies and take appropriate action against companies that inappropriately use the label of MD, physician or doctor in the naming of, or the promotion of their product; and be it further

36           RESOLVED, that the advertising of CBD as a component of marijuana be  
37 banned from places that children frequent and ~~to ask the State Legislature to create that~~  
38 ISMS support or cause to be introduced legislation to prohibit companies from selling  
39 CBD products in Illinois if they make any unproven health and therapeutic claims and to  
40 require companies to include an FDA-approved warning on CBD product labels; and be  
41 it further

42  
43           RESOLVED, that the Illinois AMA delegation submit a resolution asking the  
44 AMA to support banning the advertising of CBD as a component of marijuana in places  
45 that children frequent; and cause to be introduced legislation to prohibit companies from  
46 selling CBD products if they make any unproven health and therapeutic claims and to  
47 require companies to include an FDA-approved warning on CBD product labels.